Search

Displaying results 3771 - 3780 of 10000 in total
  1. Drug

    Trichloroacetate

    go.drugbank.com/drugs/DB11152
    ApprovedInvestigational

    Trichloroacetate is also found in cosmetic treatments and topical formulations as a cauterant, which removes condyloma or warts on the skin. … In clinical chemistry and biochemistry, it is used as a precipitant of macromolecules including proteins, DNA and RNA.

    Categories: Compounds used in a research, industrial, or household setting
  2. Target

    Nuclear cap-binding protein subunit 2

    go.drugbank.com/bio_entities/BE0013483
    TargetHumans

    Component of the cap-binding complex (CBC), which binds co-transcriptionally to the 5' cap of pre-mRNAs and is involved in various processes such as pre-mRNA splicing, translation regulation, nonsense-mediated mRNA decay, RNA-mediated ge...

    Synonyms: NCBP 20 kDa subunit, 20 kDa nuclear cap-binding protein
  3. Drug

    Oxyphenbutazone

    go.drugbank.com/drugs/DB03585
    ApprovedWithdrawn

    Oxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.

  4. Drug

    Edoxudine

    go.drugbank.com/drugs/DB13421
    ApprovedWithdrawn

    It was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus. … The obtained product is an antiviral ointment.[L2407] The activity of edoxudine against herpes simplex virus was first recognized in 1967.

  5. Drug

    Cinnamaldehyde

    go.drugbank.com/drugs/DB14184
    Approved

    It occurs naturally in the bark of cinnamon trees and other species of the genus Cinnamomum such as camphor and cassia. Sensitivity to cinnamaldehyde may be identified with a clinical patch test.

    Synonyms: (E)-3-Phenylpropenal, (E)-3-Phenyl-propenalCategories: Compounds used in a research, industrial, or household setting
  6. Drug

    AMG-222

    go.drugbank.com/drugs/DB06011
    Experimental

  7. Drug

    Plozasiran

    go.drugbank.com/drugs/DB18997
    ApprovedInvestigational

    [L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603] … Plozasiran contains a covalently linked ligand containing three N-acetylgalactosamine (GalNAc) residues to facilitate delivery to hepatocytes where it works to reduce triglyceride levels.

  8. Drug

    Recombinant Cholera Toxin B Subunit

    go.drugbank.com/drugs/DB11643
    ApprovedInvestigational

    Recombinant Cholera Toxin B Subunit is an ingredient in the EMA-authorised product Dukoral.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Pyruvic acid

    go.drugbank.com/drugs/DB00119
    ApprovedInvestigationalNutraceutical

    (From Stedman, 26th ed) … An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures.

  10. Drug

    Zilganersen

    go.drugbank.com/drugs/DB18161
    ApprovedInvestigational

    [L64096] Alexander disease is caused by variants in the *GFAP* gene that lead to overproduction and toxic accumulation of GFAP in astrocytes, and dysfunction in astrocytes can over time damage neurons … [L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition